JP7068172B2 - インドリノン化合物および線維性疾患の処置におけるそれらの使用 - Google Patents

インドリノン化合物および線維性疾患の処置におけるそれらの使用 Download PDF

Info

Publication number
JP7068172B2
JP7068172B2 JP2018533630A JP2018533630A JP7068172B2 JP 7068172 B2 JP7068172 B2 JP 7068172B2 JP 2018533630 A JP2018533630 A JP 2018533630A JP 2018533630 A JP2018533630 A JP 2018533630A JP 7068172 B2 JP7068172 B2 JP 7068172B2
Authority
JP
Japan
Prior art keywords
compound
formula
methyl
phenyl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018533630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501910A5 (enExample
JP2019501910A (ja
Inventor
イアン ウォルターズ，
ルイーズ バーチ，
ジョセフ ヒル－カズンズ，
スティーブン ポール コリンウッド，
クリストファー スコット スティーブンソン，
Original Assignee
レスピバート・リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レスピバート・リミテツド filed Critical レスピバート・リミテツド
Publication of JP2019501910A publication Critical patent/JP2019501910A/ja
Publication of JP2019501910A5 publication Critical patent/JP2019501910A5/ja
Application granted granted Critical
Publication of JP7068172B2 publication Critical patent/JP7068172B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018533630A 2015-12-24 2016-12-23 インドリノン化合物および線維性疾患の処置におけるそれらの使用 Expired - Fee Related JP7068172B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15202764.5 2015-12-24
EP15202764 2015-12-24
PCT/GB2016/054069 WO2017109513A1 (en) 2015-12-24 2016-12-23 Indolinones compounds and their use in the treatment of fibrotic diseases

Publications (3)

Publication Number Publication Date
JP2019501910A JP2019501910A (ja) 2019-01-24
JP2019501910A5 JP2019501910A5 (enExample) 2021-07-29
JP7068172B2 true JP7068172B2 (ja) 2022-05-16

Family

ID=55068868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018533630A Expired - Fee Related JP7068172B2 (ja) 2015-12-24 2016-12-23 インドリノン化合物および線維性疾患の処置におけるそれらの使用

Country Status (30)

Country Link
US (1) US11046672B2 (enExample)
EP (2) EP3722291B1 (enExample)
JP (1) JP7068172B2 (enExample)
KR (1) KR20180128390A (enExample)
CN (1) CN109302846B (enExample)
AU (1) AU2016376011B2 (enExample)
BR (1) BR112018013033A2 (enExample)
CA (1) CA3009778A1 (enExample)
CL (1) CL2018001742A1 (enExample)
CO (1) CO2018007663A2 (enExample)
CY (1) CY1126258T1 (enExample)
DK (1) DK3722291T3 (enExample)
EA (1) EA038796B1 (enExample)
ES (2) ES2956820T3 (enExample)
FI (1) FI3722291T3 (enExample)
HR (1) HRP20230833T1 (enExample)
HU (1) HUE062784T2 (enExample)
IL (1) IL260221A (enExample)
LT (1) LT3722291T (enExample)
MX (1) MX379859B (enExample)
MY (1) MY195904A (enExample)
PH (1) PH12018501575A1 (enExample)
PL (1) PL3722291T3 (enExample)
PT (1) PT3722291T (enExample)
RS (1) RS64703B1 (enExample)
SG (1) SG11201805423TA (enExample)
SI (1) SI3722291T1 (enExample)
SM (1) SMT202300260T1 (enExample)
WO (1) WO2017109513A1 (enExample)
ZA (1) ZA201804950B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
JP7039480B2 (ja) * 2016-03-08 2022-03-22 レスピバート・リミテツド プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물
CN109678810B (zh) * 2019-01-23 2022-10-28 南京工业大学 一种1,2-氧氮杂环丁烷类化合物及其制备方法与应用
EP4061373A4 (en) * 2019-11-20 2023-11-15 Angion Biomedica Corp. METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE
CN111789842B (zh) * 2020-08-07 2021-09-21 南开大学 尼达尼布在制备用于治疗炎症性肠病的药物中的应用
KR102739882B1 (ko) * 2021-04-02 2024-12-06 연세대학교 원주산학협력단 로베글리타존을 유효성분으로 하는 안과질환 치료용 조성물
CN113200936B (zh) * 2021-05-19 2022-10-21 南京工业大学 10-甲基吩噁嗪衍生物、其锆金属有机框架材料及制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027081A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
JP2004182726A (ja) 2002-11-22 2004-07-02 Yamanouchi Pharmaceut Co Ltd ２−オキソインドリン誘導体
WO2006067168A1 (en) 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
WO2006067165A2 (en) 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2007008895A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Kinase inhibitors
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
JP7039480B2 (ja) 2016-03-08 2022-03-22 レスピバート・リミテツド プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027081A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
JP2004182726A (ja) 2002-11-22 2004-07-02 Yamanouchi Pharmaceut Co Ltd ２−オキソインドリン誘導体
WO2006067168A1 (en) 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
WO2006067165A2 (en) 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2007008895A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Kinase inhibitors
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROTH, GJ et al.，Design, Synthesis, and Evaluation of Indolinones as Inhibitors of the Transforming Growth Factor β Receptor I (TGFβRI)，Journal of Medicinal Chemistry，2010年，Vol. 53，pp. 7287-7295
ROTH, GJ et al.，Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)，Journal of Medicinal Chemistry，2009年，Vol. 52，pp. 4466-4480

Also Published As

Publication number Publication date
EP3722291A1 (en) 2020-10-14
MY195904A (en) 2023-02-27
HUE062784T2 (hu) 2023-12-28
IL260221A (en) 2018-07-31
PH12018501575A1 (en) 2019-04-15
CO2018007663A2 (es) 2018-10-10
US11046672B2 (en) 2021-06-29
PT3722291T (pt) 2023-09-22
DK3722291T3 (da) 2023-09-18
MX379859B (es) 2025-03-11
CN109302846B (zh) 2021-05-11
MX2018007852A (es) 2018-11-09
EP3722291B1 (en) 2023-07-19
FI3722291T3 (fi) 2023-09-05
HRP20230833T1 (hr) 2023-11-10
BR112018013033A2 (pt) 2018-12-04
WO2017109513A1 (en) 2017-06-29
ES2796358T3 (es) 2020-11-26
SG11201805423TA (en) 2018-07-30
PL3722291T3 (pl) 2023-11-27
CL2018001742A1 (es) 2018-11-23
SI3722291T1 (sl) 2023-10-30
EP3394048A1 (en) 2018-10-31
CN109302846A (zh) 2019-02-01
CA3009778A1 (en) 2017-06-29
LT3722291T (lt) 2023-12-11
SMT202300260T1 (it) 2023-09-06
EA201891506A1 (ru) 2019-02-28
AU2016376011B2 (en) 2021-02-11
CY1126258T1 (el) 2026-02-25
ZA201804950B (en) 2020-11-25
KR20180128390A (ko) 2018-12-03
RS64703B1 (sr) 2023-11-30
US20190337929A1 (en) 2019-11-07
ES2956820T3 (es) 2023-12-28
AU2016376011A1 (en) 2018-08-09
EP3394048B1 (en) 2020-03-11
EA038796B1 (ru) 2021-10-20
JP2019501910A (ja) 2019-01-24

Similar Documents

Publication Publication Date Title
JP7039480B2 (ja) プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用
ES2956820T3 (es) Compuestos de indolinonas y su uso en el tratamiento de enfermedades fibróticas
JP6952085B2 (ja) キナーゼ阻害剤としてのピラゾリル尿素
KR101959194B1 (ko) 신규한 피페리디노-디하이드로티에노피리미딘 설폭사이드 및 ｃｏｐｄ 및 천식을 치료하기 위한 이들의 용도
CA2913634C (en) Small molecule inhibitors of fibrosis
JP2005089334A (ja) ８−ヒドロキシアデニン化合物
KR20180088462A (ko) 수면-관련 호흡기 장애의 치료를 위한 TASK-1 및 TASK-2 채널의 차단제로서의 2-페닐-3-(피페라지노메틸)이미다조[1,2-a]피리딘 유도체
JP7080346B2 (ja) 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート
CN113260616A (zh) 用于治疗呼吸系统疾病的新型化合物
CN111620815B (zh) 手性氯喹、羟氯喹和其衍生物及其制备方法与用途
CN109153672A (zh) Trpv4拮抗剂
HK40039709A (en) Indolinones compounds and their use in the treatment of fibrotic diseases
HK40002826A (en) Indolinones compounds and their use in the treatment of fibrotic diseases
HK40003052A (en) Indole derivatives and their use as protein kinase inhibitors
HK40003052B (en) Indole derivatives and their use as protein kinase inhibitors
HK40002827A (en) Indole derivatives and their use as protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210304

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210304

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210511

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220428

R150 Certificate of patent or registration of utility model

Ref document number: 7068172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees